了解levosimendan的临床使用及其在瘤学中的未来前景
Eduarda Ribeiro1,2,3, Nuno Vale1,2,4
1OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
Biomolecules
|September 28, 2023
概括
药物重新定位为新的癌症治疗提供了更快的途径. 一种心力衰竭药物Levosimendan通过抑制癌细胞生长和增强辐射敏感性,在瘤学中显示出有前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 药物重定向通过利用已知安全性概况的现有药物来加速新疗法的开发.
- 莱沃西门丹是一种用于心力衰竭的敏感剂,具有适用于癌症治疗的药理动力学特性.
研究的目的:
- 探索用于瘤学应用的levosimendan重新利用的潜力.
- 研究levosimendan抗癌作用的机制及其与常规化疗的协同作用潜力.
主要方法:
- 对levosimendan的药理动力学和癌症模型中的临床前研究现有文献的审查.
- 对levosimendan对癌细胞迁移,辐射敏感性和器官保护的影响进行分析.
- 在膀癌细胞中与5-甲 (5-FU) 联合治疗的评估.
主要成果:
- 莱沃西门丹证明抑制了癌细胞迁移,并增加了低毒细胞对辐射的敏感性.
- 该药物通过线粒体通道激活表现出器官保护作用.
- 当levosimendan与-5-FU在膀癌细胞中结合使用时,观察到协同作用的抗癌作用.
结论:
- 莱沃西门丹代表了在瘤学中药物重新利用的有希望的候选者.
- 它的多方面的行动和协同潜力为新型癌症疗法提供了成本效益和时间效率高的战略.
- 需要进一步的临床试验来确认levosimendan在癌症患者中的疗效和安全性.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:26Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12